GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck & Co crashed the party.

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

One especially frightening type of cancer that is extremely difficult to detect and seems to show up more often in Black ...

This guest essay reflects the views of Dr. Richard Barakat, physician-in-chief at the Northwell Health Cancer Institute.

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.

Uterine fibroid pain treatments like medications or surgery can offer relief. Uterine fibroid pain originates from non-cancerous tumors that grow in a person's uterus. The growths vary in size and ...

Reproductive tract problems—Uterine fibroids and polyps (growths) or infections are common causes of abnormal bleeding. Precancer or cancer in the uterus, cervix (opening of the uterus), or ...

Gynecological cancers—including ovarian, uterine, cervical, vaginal and vulvar cancers—pose a significant health burden for women. While lifestyle and environmental factors contribute to cancer risk, ...